scholarly article | Q13442814 |
P356 | DOI | 10.1021/ACSCHEMBIO.8B00692 |
P698 | PubMed publication ID | 30137962 |
P50 | author | Danette Daniels | Q59753598 |
Marjeta Urh | Q90470391 | ||
Kristin M Riching | Q123019436 | ||
Mark G McDougall | Q123019459 | ||
Sarah Mahan | Q123019464 | ||
Cesear Corona | Q123019476 | ||
P2093 | author name string | Matthew B Robers | |
James D Vasta | |||
P2860 | cites work | Multiplex genome engineering using CRISPR/Cas systems | Q24609428 |
P433 | issue | 9 | |
P304 | page(s) | 2758-2770 | |
P577 | publication date | 2018-08-30 | |
P1433 | published in | ACS Chemical Biology | Q165583 |
P1476 | title | Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action | |
P478 | volume | 13 |
Q92758130 | A critical evaluation of the approaches to targeted protein degradation for drug discovery |
Q91621874 | A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity |
Q92042152 | Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay |
Q61809000 | Bivalent Ligands for Protein Degradation in Drug Discovery |
Q91623240 | Bromodomains: a new target class for drug development |
Q89810816 | Characterization of cereblon-dependent targeted protein degrader by visualizing the spatiotemporal ternary complex formation in cells |
Q90719868 | Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality |
Q92189593 | Developing degraders: principles and perspectives on design and chemical space |
Q111442197 | Development of BromoTag: A “Bump-and-Hole”–PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins |
Q90130105 | Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity |
Q98733486 | Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry |
Q61449114 | Iterative design and optimization of initially inactive Proteolysis Targeting Chimeras (PROTACs) identify VZ185 as a potent, fast and selective von Hippel-Lindau (VHL)-based dual degrader probe of BRD9 and BRD7 |
Q90476060 | NanoBiT Complementation to Monitor Agonist-Induced Adenosine A1 Receptor Internalization |
Q98159741 | Native Mass Spectrometry Can Effectively Predict PROTAC Efficacy |
Q90412606 | PROTAC Technology: Opportunities and Challenges |
Q90186445 | PROTACs- a game-changing technology |
Q92310282 | PROTACs: great opportunities for academia and industry |
Q92758119 | PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future |
Q96019158 | PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics |
Q64269515 | SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate |
Q104492147 | Targeted Protein Degradation Phenotypic Studies Using HaloTag CRISPR/Cas9 Endogenous Tagging Coupled with HaloPROTAC3 |
Q96431675 | Targeted protein degradation as a powerful research tool in basic biology and drug target discovery |
Q90032238 | Targeted protein degradation: elements of PROTAC design |
Q89926094 | The luminescent HiBiT peptide enables selective quantitation of GPCR ligand engagement and internalization in living cells |
Q99557852 | Understanding and Improving the Membrane Permeability of VH032-Based PROTACs |
Search more.